Scholarlink

<p>HSCT significantly affects systemic inflammation, cognitive function, and quality of life (QoL). This study examines the longitudinal changes in serum biomarkers (BDNF, TNF-α, IL-1β), cognitive function (MMSE), and QoL (EORTC QLQ-C30) in HSCT patients at various recovery stages. Sixty patients were grouped based on time post-HSCT: Group 1 (1&#xa0;day pre-HSCT), Group 2 (≤ 7 days post-HSCT), Group 3 (30–60 days), Group 4 (90–120 days), and Group 5 (≥ 6 months). Serum biomarkers, MMSE, and QoL scores were assessed. BDNF levels increased from 10.84 ± 3.31 ng/mL (Group 1) to 24.90 ± 3.78 ng/mL (Group 5). TNF-α and IL-1β peaked early and declined over time. MMSE scores improved from 15.8 ± 5.75 (Group 1) to 24.67 ± 5.51 (Group 5), with QoL improving significantly. HSCT leads to early cognitive and inflammatory challenges, with substantial recovery over time. Monitoring these factors can optimize post-transplant care.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neurobehavioral Changes, Quality of Life, Serum Brain-Derived Neurotrophic Factor and Proinflammatory Cytokine Levels After Hematopoietic Stem Cell Transplantation in Patients with Hematological Malignancies

  • 期刊论文

  • 发表日期：

    2026年3月19日

查看全文
  • Inzila Islam,
  • Aakriti Garg,
  • Dinesh Bhurani,
  • Saman Anees,
  • Mohammed Al-Zahrani,
  • Mohd Ashif Khan

摘要

HSCT significantly affects systemic inflammation, cognitive function, and quality of life (QoL). This study examines the longitudinal changes in serum biomarkers (BDNF, TNF-α, IL-1β), cognitive function (MMSE), and QoL (EORTC QLQ-C30) in HSCT patients at various recovery stages. Sixty patients were grouped based on time post-HSCT: Group 1 (1 day pre-HSCT), Group 2 (≤ 7 days post-HSCT), Group 3 (30–60 days), Group 4 (90–120 days), and Group 5 (≥ 6 months). Serum biomarkers, MMSE, and QoL scores were assessed. BDNF levels increased from 10.84 ± 3.31 ng/mL (Group 1) to 24.90 ± 3.78 ng/mL (Group 5). TNF-α and IL-1β peaked early and declined over time. MMSE scores improved from 15.8 ± 5.75 (Group 1) to 24.67 ± 5.51 (Group 5), with QoL improving significantly. HSCT leads to early cognitive and inflammatory challenges, with substantial recovery over time. Monitoring these factors can optimize post-transplant care.